Post Profile

Novartis gets U.S. approval for bigger dose Glatopa MS treatment

ZURICH (Reuters) - Novartis's Sandoz division said on Tuesday it has won approval in the United States for a larger dosage of its Glatopa treatment for multiple sclerosis patients.
read more


Related Posts

Novartis gets European OK for biosimilar of Amgen's Enbrel

Health : Reuters: Health

ZURICH (Reuters) - Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis.

Mylan says FDA approves its generic multiple sclerosis treatment

Health : Reuters: Health

(Reuters) - Mylan NV said the U.S. Food and Drug Administration has approved two doses of its generic version of Teva's Copaxone used to treat patients with relapsing forms of multiple sclerosis.

Novartis says Votubia receives EU approval for new indication

Health : Reuters: Health

ZURICH (Reuters) - Novartis has broaded the indications for its Votubia drug, the company said on Tuesday, when the European Union approved its use to treat refractory partial-onset seizures in patients with tuberous sclerosis compl...

Novartis warns of U.S. price pressure on Sandoz generics

Health : Reuters: Health

ZURICH (Reuters) - Novartis warned on Wednesday that price pressure on its generics drugs in the United States has intensified in the second quarter, cutting into its Sandoz division's sales growth in the world's largest healthcare ...

Novartis to speed up bid for MS drug approval, changes target

Health : Reuters: Health

ZURICH (Reuters) - Novartis said on Tuesday it would accelerate its bid to win approval for its experimental multiple sclerosis (MS) drug BAF312 and said it was now targeting patients at an earlier stage of the neurological disease.


Copyright © 2016 Regator, LLC